Merck inks $200 million deal for Hengrui's midstage heart disease drug
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The products will be manufactured in Goa India and marketed & distributed in Australian markets
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring
Subscribe To Our Newsletter & Stay Updated